HCV VIRAL KINETICS AND DETERMINANTS OF RELAPSE (HIV)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 对于感染艾滋病毒的患者来说，丙型肝炎病毒(丙型肝炎病毒)的混合感染已成为导致死亡和发病的主要原因。尽管目前的治疗标准(聚乙二醇干扰素和利巴韦林)最近取得了进展，但尽管最初的病毒学反应良好，但单一感染和合并感染的患者经常没有反应或将复发。病毒动力学研究有助于确定抗病毒药物的作用机制和疗效。在聚乙二醇化干扰素和利巴韦林治疗的前12周，我们将比较合并感染和单一感染的丙型肝炎病毒感染者血清和肝外部位的丙型肝炎病毒衰变动力学。我们假设，在治疗期间，与单一感染患者相比，合并感染患者所有隔室中的丙型肝炎病毒RNA下降速度会更慢，这种第一和第二阶段动力学的下降将预测对聚乙二醇干扰素-利巴韦林治疗的长期反应频率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. For HIV infected patients, Hepatitis C virus (HCV) coinfection has emerged as a leading cause of mortality and morbidity. Despite recent advances in treatment with the current standard of care (peginterferon and ribavirin), both mono- and coinfected patients frequently do not respond or will relapse despite a favorable initial virologic response. The study of viral kinetics is useful in identifying antivirals' mechanisms of action and efficacy. We will compare HCV decay kinetics in serum and extrahepatic sites among coinfected versus HCV monoinfected patients during the first 12 weeks of pegylated interferon and ribavirin therapy. We hypothesize that coinfected patients will demonstrate a slower decline in HCV RNA in all compartments during therapy compared with mono-infected patients and that this decline in phase 1 and 2 kinetics will predict the frequency of long term response to peginterferon-ribavirin therapy.